Evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond

被引：0
|
作者：
Nasrallah, Henry A. [1 ]
机构：
[1] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2007年 / 68卷
关键词：
D O I：
暂无
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - Alzheimer disease trial methodology
    Schneider, LS
    Tariot, PN
    Lyketsos, CG
    Dagerman, KS
    Davis, KL
    Davis, S
    Hsiao, JK
    Jeste, DV
    Katz, IR
    Olin, JT
    Pollock, BG
    Rabins, PV
    Rosenheck, RA
    Small, GW
    Lebowitz, B
    Lieberman, JA
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2001, 9 (04): : 346 - 360
  • [22] Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale
    Keefe, RSE
    Mohs, RC
    Bilder, RM
    Harvey, PD
    Green, MF
    Meltzer, HY
    Gold, JM
    Sano, M
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 45 - 55
  • [23] The Impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on Prescribing Practices: An Analysis of Data From a Large Midwestern State
    Berkowitz, Rachel L.
    Patel, Urvashi
    Ni, Quanhong
    Parks, Joseph J.
    Docherty, John P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 498 - 503
  • [24] Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies
    Davis, SM
    Koch, GG
    Davis, CE
    LaVange, LM
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 73 - 80
  • [25] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
  • [26] The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Byerly, MJ
    Glick, ID
    Canive, JM
    McGee, MF
    Simpson, GM
    Stevens, MC
    Lieberman, JA
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 15 - 31
  • [27] Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    Hermes, Eric D. A.
    Sokoloff, Daniel
    Stroup, T. Scott
    Rosenheck, Robert A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 526 - 532
  • [28] Life Satisfaction Among Individuals With Schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Study
    Fervaha, Gagan
    Agid, Ofer
    Takeuchi, Hiroyoshi
    Foussias, George
    Remington, Gary
    AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (09): : 1061 - 1062
  • [29] The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data
    Ozzoude, Miracle
    Nakajima, Shinichiro
    Plitman, Eric
    Chung, Jun Ku
    Kim, Julia
    Iwata, Yusuke
    Caravaggio, Fernando
    Takeuchi, Hiroyoshi
    Uchida, Hiroyuki
    Graff-Guerrero, Ariel
    Gerretsen, Philip
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 89 : 207 - 213
  • [30] Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia
    Beaudoin, M.
    Potvin, S.
    Hudon, A.
    Giguere, C. -E.
    Dumais, A.
    EUROPEAN PSYCHIATRY, 2021, 64 : S157 - S157
12345